Patents by Inventor Kent Thudium

Kent Thudium has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST OX-40 AND USES THEREOF
    Publication number: 20230272100
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: August 11, 2022
    Publication date: August 31, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
  • Antibodies against OX-40 and uses thereof
    Patent number: 11466092
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: October 11, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
  • ANTIBODIES AGAINST OX-40 AND USES THEREOF
    Publication number: 20200399385
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 24, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
  • Antibodies against OX40 and uses thereof
    Patent number: 10683357
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 16, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
  • ANTIBODIES AGAINST OX40 AND USES THEREOF
    Publication number: 20180237534
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: May 26, 2016
    Publication date: August 23, 2018
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Maria RODRIGUEZ, Xiang SHAO, Mohan SRINIVASAN, Brenda L. STEVENS, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Christine HUANG, Maria JURE-KUNKEL, Zheng YANG, Yan FENG, Patrick GUIRNALDA, Nils LONBERG, Bryan C. BARNHART, Aaron P. YAMNIUK, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL, Praveen AANUR, Mark J. SELBY
  • ANTIBODIES AGAINST OX40 AND USES THEREOF
    Publication number: 20170306035
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 26, 2017
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
  • Antibodies against OX40 and uses thereof
    Patent number: 9644032
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 9, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
  • ANTIBODIES AGAINST OX40 AND USES THEREOF
    Publication number: 20160347849
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 1, 2016
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Maria RODRIGUEZ, Xiang SHAO, Mohan SRINIVASAN, Brenda L. STEVENS, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Christine HUANG, Maria JURE-KUNKEL, Zheng YANG, Yan FENG, Patrick GUIRNALDA, Nils LONBERG, Bryan C. BARNHART, Aaron P. YAMNIUK, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL, Praveen AANUR, Mark J. SELBY
  • Chimeric alphavirus replicon particles
    Patent number: 9255126
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 9, 2016
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Chimeric alphavirus replicon particles
    Patent number: 8158418
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: April 17, 2012
    Assignee: Novartis Vaccines & Diagnostics Inc.
    Inventors: John Polo, Silvia Perri, Kent Thudium
  • CHIMERIC ALPHAVIRUS REPLICON PARTICLES
    Publication number: 20090305344
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: February 17, 2009
    Publication date: December 10, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: John M. POLO, Silvia PERRI, Kent THUDIUM
  • CHIMERIC ALPHAVIRUS REPLICON PARTICLES
    Publication number: 20090304745
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 10, 2009
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Chimeric alphavirus replicon particles
    Patent number: 7572453
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: August 11, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium
  • Chimeric alphavirus replicon particles
    Patent number: 7531180
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: May 12, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc
    Inventors: John M. Polo, Silvia Perri, Kent Thudium
  • Chimeric alphavirus replicon particles
    Publication number: 20060292175
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: April 3, 2006
    Publication date: December 28, 2006
    Applicant: Chiron Corporation
    Inventors: John Polo, Silvia Perri, Kent Thudium
  • Cytomegalovirus intron a fragments
    Publication number: 20050191727
    Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
    Type: Application
    Filed: April 11, 2005
    Publication date: September 1, 2005
    Applicant: Chiron Corporation
    Inventors: Kent Thudium, Mark Selby
  • Antibodies to hepatitis C virus asialoglycoproteins
    Publication number: 20050089843
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 28, 2005
    Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • CYTOMEGALOVIRUS INTRON A FRAGMENTS
    Publication number: 20050079488
    Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
    Type: Application
    Filed: October 12, 2001
    Publication date: April 14, 2005
    Inventors: Kent Thudium, Mark Selby
  • Chimeric alphavirus replicon particles
    Publication number: 20030232324
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: December 4, 2002
    Publication date: December 18, 2003
    Applicant: Chiron Corporation
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Chimeric alphavirus replicon particles
    Publication number: 20030148262
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Application
    Filed: April 11, 2002
    Publication date: August 7, 2003
    Inventors: John M. Polo, Silvia Perri, Kent Thudium